Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Goldstein

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
JAMA Oncology|December 10, 2017
A Policy That Encourages Wastage of Expensive Medications-The JW ModifierDaniel A Goldstein, Abigail Hirsch
JAMA Oncology|March 10, 2018
The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?Bishal Gyawali, Daniel A Goldstein
The Oncologist|July 8, 2016
Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the WorldDaniel A Goldstein, Michal Sarfaty
Cancer Chemotherapy and Pharmacology|October 21, 2019
Alternative dosing regimens for atezolizumab: right dose, wrong frequencyDaniel A Goldstein, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-LetterDaniel A Goldstein, Mark J Ratain
The American Journal of Managed Care|December 1, 2015
Strategies for individualizing management of patients with metastatic melanoma: a managed care perspectiveDaniel A Goldstein, Simon B Zeichner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2018
Time Is Money: Optimizing the Scheduling of NivolumabMark J Ratain, Daniel A Goldstein
The Lancet. Neurology|June 20, 2014
Neurodevelopmental toxicity: still more questions than answersDaniel A Goldstein, David A Saltmiras
The Oncologist|December 8, 2018
Patient-Centered Oncology or Population-Centered Oncology-Which Do We Want, and Which Tradeoffs Are We Willing To Accept?Daniel A Goldstein, Robert B Den
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2022
Cost Savings and Increased Access With Ultra-Low-Dose ImmunotherapyAaron P Mitchell, Daniel A Goldstein
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
JAMA Oncology|December 10, 2017
A Policy That Encourages Wastage of Expensive Medications-The JW ModifierDaniel A Goldstein, Abigail Hirsch
JAMA Oncology|March 10, 2018
The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?Bishal Gyawali, Daniel A Goldstein
The Oncologist|July 8, 2016
Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the WorldDaniel A Goldstein, Michal Sarfaty
Cancer Chemotherapy and Pharmacology|October 21, 2019
Alternative dosing regimens for atezolizumab: right dose, wrong frequencyDaniel A Goldstein, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-LetterDaniel A Goldstein, Mark J Ratain
The American Journal of Managed Care|December 1, 2015
Strategies for individualizing management of patients with metastatic melanoma: a managed care perspectiveDaniel A Goldstein, Simon B Zeichner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2018
Time Is Money: Optimizing the Scheduling of NivolumabMark J Ratain, Daniel A Goldstein
The Lancet. Neurology|June 20, 2014
Neurodevelopmental toxicity: still more questions than answersDaniel A Goldstein, David A Saltmiras
The Oncologist|December 8, 2018
Patient-Centered Oncology or Population-Centered Oncology-Which Do We Want, and Which Tradeoffs Are We Willing To Accept?Daniel A Goldstein, Robert B Den
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2022
Cost Savings and Increased Access With Ultra-Low-Dose ImmunotherapyAaron P Mitchell, Daniel A Goldstein
Pageof 14